Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics Balance Sheet

Financials in millions ILS. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	5.01	14.22	17.52	2.66	20.45
Cash & Cash Equivalents	5.01	14.22	17.52	2.66	20.45
Cash Growth	-64.76%	-18.85%	558.76%	-87.00%	-4.50%
Receivables	0	0	0	0.34	0.19
Other Current Assets	0.44	0.16	0.33	0	0
Total Current Assets	5.45	14.37	17.84	3	20.64
Property, Plant & Equipment	12.03	12.7	14.19	12.93	11.89
Other Long-Term Assets	0	0	0	0.13	0.14
Total Long-Term Assets	12.03	12.7	14.19	13.06	12.03
Total Assets	17.47	27.07	32.04	16.06	32.67
Accounts Payable	1.38	1.96	2.07	1.2	5.16
Current Debt	0.4	0.38	0.38	17.24	0.2
Other Current Liabilities	0	0	0	-0.32	0
Total Current Liabilities	1.78	2.34	2.44	18.12	5.35
Long-Term Debt	20.17	21.16	28.61	1.72	36.86
Other Long-Term Liabilities	0.1	5.33	0	0.35	8.82
Total Long-Term Liabilities	20.26	26.49	28.61	2.07	45.68
Total Liabilities	22.04	28.83	31.05	20.18	51.03
Total Debt	20.56	21.54	28.99	18.96	37.05
Debt Growth	-4.55%	-25.68%	52.90%	-48.84%	39.13%
Retained Earnings	-122.34	-115.84	-110.04	-91.67	-90.42
Comprehensive Income	-1.74	-2.01	-2.06	0	0
Shareholders' Equity	-4.57	-1.76	0.98	-4.12	-18.36
Net Cash / Debt	-15.55	-7.33	-11.47	-16.3	-16.6
Net Cash Per Share	-0.01	-0.01	-0.02	-0.04	-0.05
Working Capital	3.67	12.03	15.4	-15.12	15.29
Book Value Per Share	-11.70	-9.34	6.96	-37.18	-224.84

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).